{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:59:18Z","timestamp":1790632758373,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s10741-005-2345-1","type":"journal-article","created":{"date-parts":[[2005,6,9]],"date-time":"2005-06-09T13:35:03Z","timestamp":1118324103000},"page":"23-29","source":"Crossref","is-referenced-by-count":174,"title":["Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis"],"prefix":"10.1007","volume":"10","author":[{"given":"Domenic A.","family":"Sica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"2345_CR1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11906-004-0069-6","volume":"6","author":"WH Frishman","year":"2004","unstructured":"Frishman WH, Stier CT. Aldosterone and aldosterone antagonism in systemic hypertension. Curr Hypertens Rep 2004;6:195\u2013200.","journal-title":"Curr Hypertens Rep"},{"key":"2345_CR2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.HDX.0000061698.20666.aa","volume":"5","author":"CT Stier","year":"2003","unstructured":"Stier CT, Koenig S, Lee DY, et al. Aldosterone and aldosterone antagonism in cardiovascular disease. Heart Disease 2003;5:102\u2013118.","journal-title":"Heart Disease"},{"key":"2345_CR3","first-page":"52","volume":"61","author":"F Mantero","year":"2000","unstructured":"Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000;61:52\u201360.","journal-title":"Ann Endocrinol (Paris)"},{"key":"2345_CR4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/106002809002400112","volume":"24","author":"HA Skluth","year":"1990","unstructured":"Skluth HA, Gums JG. Spironolactone: A re-examination. DICP1990;24:52\u201359.","journal-title":"DICP"},{"key":"2345_CR5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2165\/00003495-200363190-00001","volume":"63","author":"D Liew","year":"2003","unstructured":"Liew D, Krum H. Aldosterone receptor antagonists for hypertension. Drugs 2003;63:1963\u20131972.","journal-title":"Drugs"},{"key":"2345_CR6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"2345_CR7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003;348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"2345_CR8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","volume":"225","author":"DJ Greenblatt","year":"1973","unstructured":"Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1973;225:40\u201343.","journal-title":"JAMA"},{"key":"2345_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004;217:27\u201331.","journal-title":"Mol Cell Endocrinol"},{"key":"2345_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","volume":"217","author":"J Menard","year":"2004","unstructured":"Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol2004;217:45\u201352.","journal-title":"Mol Cell Endocrinol"},{"key":"2345_CR11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/clpt.1986.219","volume":"40","author":"HW Overdiek","year":"1986","unstructured":"Overdiek HW, Merkus FW. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986;40:531\u2013536.","journal-title":"Clin Pharmacol Ther"},{"key":"2345_CR12","first-page":"117","volume-title":"Diuretics: Physiology, Pharmacology and Clinical Use","author":"CR Shackleton","year":"1986","unstructured":"Shackleton CR, Wong NLM, Sutton RA. Distal (potassium-sparing) diuretics. In: Dirks JH, Sutton RAL, eds. Diuretics: Physiology, Pharmacology and Clinical UsePhiladelphia: WB Saunders, 1986:117."},{"key":"2345_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","volume":"8","author":"A Karim","year":"1978","unstructured":"Karim A. Spironolactone: Disposition, Metabolism, Pharmacodynamics and bioavailability. Drug Metab Rev 1978;8:151.","journal-title":"Drug Metab Rev"},{"key":"2345_CR14","first-page":"249","volume":"[A]5","author":"FWHM Merkus","year":"1983","unstructured":"Merkus FWHM, Overdiek JWPM, Cilissen J, et al. Pharmacokinetics of spironolactone after a single dose: Evaluation of the true canrenone serum concentrations during 24 hours. Clin Exp Hypertens 1983;[A]5:249.","journal-title":"Clin Exp Hypertens"},{"key":"2345_CR15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989;29:342.","journal-title":"J Clin Pharmacol"},{"key":"2345_CR16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1023\/A:1012168020545","volume":"14","author":"N Takamura","year":"1997","unstructured":"Takamura N, Maruyama T, Ahmed S, et al. Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm Res 1997;14:522\u2013526.","journal-title":"Pharm Res"},{"key":"2345_CR17","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","volume":"102","author":"I Sungaila","year":"1992","unstructured":"Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992;102:1680\u2013 1685.","journal-title":"Gastroenterology"},{"key":"2345_CR18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11906-004-0029-1","volume":"6","author":"N McLaughlin","year":"2004","unstructured":"McLaughlin N, Gehr TWB, Sica DA. Aldosterone receptor antagonism and end-stage renal disease. Curr Hypertens Rep 2004;6:327\u2013330.","journal-title":"Curr Hypertens Rep"},{"key":"2345_CR19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, et al. Pharmacokinetics and metabolism of [14C] eplerenone after oral administration to humans. Drug Metab Dispos 2003;31:1448\u20131455.","journal-title":"Drug Metab Dispos"},{"key":"2345_CR20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1124\/dmd.30.12.1344","volume":"30","author":"CS Cook","year":"2002","unstructured":"Cook CS, Berry LM, Kim DH, et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002;30:1344\u20131351.","journal-title":"Drug Metab Dispos"},{"key":"2345_CR21","unstructured":"Ravis WR, Reid S, Roniker B, Sica DA. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. Journal of Clinical Pharmacology (in press)."},{"key":"2345_CR22","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ. Eplerenone. Cardiovascular protection. Circulation2003;107:2512\u20132518.","journal-title":"Circulation"},{"key":"2345_CR23","first-page":"1332","volume":"22","author":"DS Tolbert","year":"2002","unstructured":"Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone in special populations. Pharmacotherapy2002;22:1332.","journal-title":"Pharmacotherapy"},{"key":"2345_CR24","first-page":"1331","volume":"22","author":"DS Tolbert","year":"2002","unstructured":"Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone coadministered with other medications. Pharmacotherapy2002;22:1331.","journal-title":"Pharmacotherapy"},{"key":"2345_CR25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/00498250310001649341","volume":"34","author":"CS Cook","year":"2004","unstructured":"Cook CS, Berry LM, Burton E. Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica2004;34:215\u2013228.","journal-title":"Xenobiotica"},{"key":"2345_CR26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259\u20131265.","journal-title":"Am J Cardiol"},{"key":"2345_CR27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","volume":"39","author":"J Santos","year":"2003","unstructured":"Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003;39:187\u2013192.","journal-title":"J Hepatol"},{"key":"2345_CR28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709\u2013716.","journal-title":"Am J Hypertens"},{"key":"2345_CR29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925\u2013930.","journal-title":"Am J Hypertens"},{"key":"2345_CR30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt197925133","volume":"25","author":"G Schrijver","year":"1979","unstructured":"Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979;25:33\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"2345_CR31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.1980.75","volume":"27","author":"LE Ramsay","year":"1980","unstructured":"Ramsay LE, Hettiarachchi J, Fraser R, Morton JJ. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther 1980;27:533\u2013543.","journal-title":"Clin Pharmacol Ther"},{"key":"2345_CR32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/000331977202301007","volume":"23","author":"MJ Kert","year":"1972","unstructured":"Kert MJ, Tarr LW, Franklin S, et al. Experience with the use of an aldosterone antagonist in selected hypertensive patients. Angiology 1972;23:617\u2013627.","journal-title":"Angiology"},{"key":"2345_CR33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJM197412052912309","volume":"291","author":"SC Lowder","year":"1974","unstructured":"Lowder SC, Liddle GW. Prolonged alteration of renin responsiveness after spironolactone therapy. A cause of false-negative testing for low-renin hypertension. N Engl J Med 1974;291:1243\u20131244.","journal-title":"N Engl J Med"},{"key":"2345_CR34","doi-asserted-by":"crossref","first-page":"40A","DOI":"10.1016\/0002-9149(93)90244-7","volume":"71","author":"DC Schohn","year":"1993","unstructured":"Schohn DC, Jahn HA, Pelletier BC. Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993;71:40A\u201345A.","journal-title":"Am J Cardiol"},{"key":"2345_CR35","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831\u20131838.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"2345_CR36","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15(Suppl 1):A24.","journal-title":"Am J Hypertens"},{"key":"2345_CR37","doi-asserted-by":"crossref","unstructured":"The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902\u2013907.","DOI":"10.1016\/S0002-9149(96)00465-1"},{"issue":"Suppl 1","key":"2345_CR38","doi-asserted-by":"crossref","first-page":"A100","DOI":"10.1016\/S0895-7061(03)00335-2","volume":"16","author":"DA Sica","year":"2003","unstructured":"Sica DA. Eplerenone and serum potassium change\u2014relationship to renal function. Am J Hypertens 2003:16(Suppl 1):A100.","journal-title":"Am J Hypertens"},{"key":"2345_CR39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543\u2013551.","journal-title":"N Engl J Med"},{"key":"2345_CR40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1527-5299.2004.02814.x","volume":"10","author":"DA Sica","year":"2004","unstructured":"Sica DA, Hess M. Aldosterone receptor antagonism: Interface with hyperkalemia in heart failure. Cong Heart Fail 2004;10:259\u2013264.","journal-title":"Cong Heart Fail"},{"key":"2345_CR41","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0002-9149(02)02580-8","volume":"90","author":"DA Blaustein","year":"2002","unstructured":"Blaustein DA, Babu K, Reddy A, et al. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol 2002;90:662\u2013663.","journal-title":"Am J Cardiol"},{"key":"2345_CR42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","volume":"10","author":"M Svensson","year":"2004","unstructured":"Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure ? J Card Fail2004;10:297\u2013303.","journal-title":"J Card Fail"},{"key":"2345_CR43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","volume":"41","author":"B Bozkurt","year":"2003","unstructured":"Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211\u2013214.","journal-title":"J Am Coll Cardiol"},{"key":"2345_CR44","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archinte.160.11.1605","volume":"160","author":"D Charytan","year":"2000","unstructured":"Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med 2000;160:1605\u20131611.","journal-title":"Arch Intern Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-005-2345-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-005-2345-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-005-2345-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:01:12Z","timestamp":1559242872000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-005-2345-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["2345"],"URL":"https:\/\/doi.org\/10.1007\/s10741-005-2345-1","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}